Eliem Therapeutics Stock Cash And Equivalents
| ELYMDelisted Stock | USD 5.16 0.09 1.78% |
Eliem Therapeutics fundamentals help investors to digest information that contributes to Eliem Therapeutics' financial success or failures. It also enables traders to predict the movement of Eliem Stock. The fundamental analysis module provides a way to measure Eliem Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eliem Therapeutics stock.
Eliem |
Eliem Therapeutics Company Cash And Equivalents Analysis
Eliem Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Eliem Therapeutics Cash And Equivalents | 122.95 M |
Most of Eliem Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eliem Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Eliem Therapeutics has 122.95 M in Cash And Equivalents. This is 85.02% lower than that of the Biotechnology sector and 72.5% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 95.45% higher than that of the company.
Eliem Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eliem Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eliem Therapeutics could also be used in its relative valuation, which is a method of valuing Eliem Therapeutics by comparing valuation metrics of similar companies.Eliem Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Eliem Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 122.66 M | |||
| Shares Outstanding | 67.06 M | |||
| Shares Owned By Insiders | 10.38 % | |||
| Shares Owned By Institutions | 77.67 % | |||
| Number Of Shares Shorted | 1.15 M | |||
| Price To Book | 1.56 X | |||
| EBITDA | (40.27 M) | |||
| Net Income | (35.12 M) | |||
| Cash And Equivalents | 122.95 M | |||
| Cash Per Share | 4.63 X | |||
| Total Debt | 349 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 17.48 X | |||
| Book Value Per Share | 3.33 X | |||
| Cash Flow From Operations | (20.6 M) | |||
| Short Ratio | 4.07 X | |||
| Earnings Per Share | (2.22) X | |||
| Target Price | 4.5 | |||
| Beta | -0.35 | |||
| Market Capitalization | 346.03 M | |||
| Total Asset | 110.47 M | |||
| Retained Earnings | (155.98 M) | |||
| Working Capital | 107.42 M | |||
| Net Asset | 110.47 M |
About Eliem Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eliem Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eliem Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eliem Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |